🇺🇸 FDA
Patent

US 11020492

Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

granted A61KA61K2035/124A61K31/7088

Quick answer

US patent 11020492 (Gene correction of SCID-related genes in hematopoietic stem and progenitor cells) held by Sangamo Therapeutics, Inc. expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2035/124, A61K31/7088, A61K35/545, A61K48/00